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Universitario Gregorio Marañón, Complutense University of Madrid, 6Department of Infectious Diseases, Hospital Ramón y Cajal, and 7Lung
Transplant Department, Hospital Universitario Puerta de Hierro, Madrid, 8Infectious Disease Unit, Hospital Universitario Marqués de Valdecilla,
University of Cantabria, Santander, 9Infectious Disease Unit, Hospital Universitario La Fe, Valencia, and 10Infectious Disease Unit, Hospital
Universitario Reina Sofı́a, University of Córdoba, Córdoba, Spain
Background. Solid-organ transplant (SOT) recipients are classically considered to be at increased risk for
listeriosis. However, risk factors for this infection have not been assessed.
Methods. We carried out a multicenter, matched case-control study (1:2 ratio) from January 1995 through
December 2007. Control subjects were matched for center, transplant type, and timing. Conditional logistic
regression was performed to identify independent risk factors. Clinical features and outcomes for all case patients
were reviewed.
Results. Thirty patients (0.12%) with cases of listeriosis were identified among 25,997 SOT recipients at 15
Spanish transplant centers. In a comparison of case patients with 60 matched control subjects, the following
independent risk factors for listeriosis were identified: diabetes mellitus (odds ratio [OR], 5.6; 95% confidence
interval [CI], 1.6–19.6; ), history of cytomegalovirus infection or disease within the preceding 6 monthsP p .007
(OR, 35.9; 95% CI, 2.1–620; ), receipt of high-dose prednisone within the preceding 6 months (OR, 6.2;P p .014
95% CI, 1.8–21.1; ), and trimethoprim-sulfamethoxazole (TMP-SMZ) prophylaxis (OR, 0.07; 95% CI,P p .003
0.006–0.76; ). Twenty-six patients (86.7%) had bacteremia, and 7 had shock at presentation. OtherP p .029
manifestations included meningoencephalitis (10 cases), spontaneous peritonitis (2), pleural empyema (1), brain
abscesses (1), and liver abscesses (1). The 30-day mortality rate was 26.7% (8 of 30 patients died).
Conclusions. Listeriosis in SOT recipients is uncommon but causes high mortality. Diabetes mellitus, cyto-
megalovirus infection or disease, and receipt of high-dose steroids are independent risk factors for this infection,
whereas TMP-SMZ prophylaxis is a protective factor.
Listeria monocytogenes is an environmental gram-pos-
itive, motile bacillus which has the ability to survive
and multiply in phagocytic host cells. The main route
of infection acquisition is through the intestinal tract
after ingestion of contaminated food products, as well
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as from mother to child, either transplacentally or dur-
ing childbirth. L. monocytogenes is a rare cause of ill-
ness among the general population. However, for some
groups, including newborn infants, pregnant women,
elderly patients, and immunocompromised hosts, in
particular, this organism is an important cause of life-
threatening bacteremia and meningoencephalitis [1].
Solid-organ transplant (SOT) recipients are typically
considered to be at increased risk for acquiring liste-
riosis because of immunosuppressive therapy–related
deficiencies in cellular immune function [2, 3]. Nev-
ertheless, although cases of listeriosis occurring in SOT
recipients have been sporadically reported [4–9], com-
prehensive information on this infection in this pop-
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ulation is particularly scarce. Significantly, risk factors for lis-
teriosis in SOT recipients have not been formally assessed. We
conducted the present multicenter study to identify the risk
factors for sporadic listeriosis in SOT recipients with a 1:2
matched case-control study design and to review the clinical
features, microbiological characteristics, and outcomes for all
case patients.
MATERIALS AND METHODS
Setting and study population. The study was conducted in
15 Spanish tertiary care hospitals with active organ transplan-
tation programs, including liver, kidney, heart, lung, pancreas,
intestinal, and multivisceral transplantation. All patients with
culture-proven listeriosis from January 1995 through Decem-
ber 2007 were included in the analysis. Patients were identified
from the hospital microbiology and transplantation program
databases; initial identification was followed by a detailed re-
view of patient medical records. The study was approved by
the institutional review boards of the participating transplan-
tation centers.
For the purposes of risk factor analysis, a matched case-
control study (1:2 ratio) was performed. Two control subjects
were included for each case patient with listeriosis. The control
subjects were matched for 3 characteristics: (1) institution, (2)
type of transplantation, and (3) time of transplantation. The
recipients who underwent transplants immediately before and
after the index case patient and who survived at least as long
as the time to diagnosis of listeriosis were categorized as con-
trol subjects.
Clinical data and definitions. For the case patients, the
“time of event” was defined as the time of Listeria infection di-
agnosis; for the control subjects, the time of Listeria infection
in the corresponding case patient was used. Variables analyzed
for both case patients and control subjects included patient
demographic data, transplant type, prior transplantation, pres-
ence of diabetes mellitus, immunosuppressive drugs at the time
of the event, an elevated mean calcineurin inhibitor level within
the preceding 30 days (115 mg/mL for tacrolimus and 1300 ng/
mL for cyclosporin), history of high-dose prednisone therapy
within the preceding 6 months (20 mg of prednisone for 1
month or 12 pulses of 1 g of intravenous methylprednisolone),
receipt of a lymphocyte-depleting antibody within the preced-
ing 12 months, trimethoprim-sulfamethoxazole (TMP-SMX)
prophylaxis at the time of the event, allograft rejection within
the preceding 6 months, history of cytomegalovirus (CMV)
infection or disease within the preceding 6 months, mean lym-
phocyte and neutrophil counts within 30 days of the event,
and mortality rates at 30 days and 1 year after the event.
For all case patients, clinical characteristics and laboratory
data at the time of Listeria infection, treatment, and outcomes
were exhaustively evaluated. Hypoalbuminemia at the time of
Listeria infection was considered to be present when the serum
albumin level was !3 g/L. Renal impairment was defined as a
serum creatinine level 11.5 mg/dL. Meningoencephalitis was
considered to be present in case of culture-proven Listeria in-
fection and suggestive neurological symptoms not attributable
to any other etiology, even if cerebrospinal fluid (CSF) cultures
had negative results or were not performed. CMV infection
was diagnosed by growing the virus in vitro, finding evidence
of viral infection by intracytoplasmic or intranuclear inclusions
or by antibody-based staining techniques for CMV in histo-
pathologic sections or by finding evidence of replication using
nucleic acid–based assays or antigenemia studies. CMV disease
was defined as evidence of CMV infection with attributable
symptoms, as described elsewhere [10].
Microbiological studies. Each hospital’s microbiology lab-
oratory identified organisms as L. monocytogenes and per-
formed susceptibility testing. L. monocytogenes strains were
identified according to their colony characteristics, Gram stain
morphology, motility, catalase activity and conventional mi-
crobiological procedures [11]. Serotyping was performed using
specific antisera (Difco; Becton Dickinson). Susceptibility test-
ing was performed with the microdilution method according
to the guidelines of the Clinical Laboratory Standards Institute
2006 [12]. The strains with minimal inhibitory concentration
(MIC) of ampicillin 2 mg/L and MIC of TMP-SMZ (0.5
and 9.5 mg/L), were considered to be susceptible according
to Clinical Laboratory Standards Institute criteria.
Statistical analysis. To detect statistically significant dif-
ferences between specified groups, we used the x2 test with
continuity correction for categorical variables and the Student’s
t test for continuous variables. Univariate odds ratios (OR)
were calculated for the potential risk factors for Listeria infec-
tion. Multivariable conditional logistic-regression analysis of
factors potentially associated with Listeria infection included
all statistically significant variables in univariate analysis and
all clinically important variables, whether they were statistically
significant or not [13]. The analysis was performed with the
stepwise logistic-regression model of the SPSS software package
(SPSS). The Mantel-Haenszel test was used to analyze trends
in the frequency of listeriosis over time. In all analyses, we
considered P values !.05 to be statistically significant. All re-
ported P values are 2-tailed.
RESULTS
Epidemiology. Thirty L. monocytogenes infections were iden-
tified among 25,997 transplant recipients; infections were iden-
tified at 10 of the 15 participating hospitals. This figure rep-
resented 0.12% of all transplant recipients and included 14
(0.18%) of 7901 liver recipients, 8 (0.06%) of 12,390 kidney
recipients, 4 (0.12%) of 3260 heart recipients, 2 (0.12%) of
1729 lung recipients, and 2 (0.29%) of 677 multivisceral re-
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(n p 60) OR (95% CI) P
Male sex 17 (56.7) 42 (70.0) 1.78 (0.72–4.43) .21
Age, median years (range) 58.6 (32–75) 56.3 (21–73) 1.03 (0.99–1.08) .10
Diabetes mellitus 15 (50.0) 9 (15.0) 5.67 (2.07–15.51) !.001
Receipt of prior transplant 3 (10.0) 5 (8.3) 1.22 (0.27–5.49) 1.99
Multivisceral transplant 2 (6.7) 4 (6.7) 1.00 (0.17–5.79) 1.99
Receipt of prophylaxis with TMP-SMZ 3 (10.3) 12 (20.3) 0.45 (0.12–1.75) .36
Receipt of antifungal prophylaxis 5 (17.2) 10 (16.9) 1.02 (0.31–3.32) 1.99
Receipt of CMV prophylaxis 2 (6.9) 3 (5.1) 1.38 (0.21–8.77) 1.99
CMV infection or disease within preceding 6 months 8 (26.7) 2 (3.3) 10.54 (2.08–53.57) .002
Prednisone dose at the time of the eventa,
median mg (range) 15 (2.5–45) 10 (1.25–75.0) 1.03 (0.99–1.08) .159
Receipt of high-dose prednisone within preceding 6
monthsb 17 (58.6) 10 (18.2) 6.37 (2.33–17.46) !.001
Elevated median calcineurin inhibitor level within
preceding 30 daysc 6 (20.0) 8 (13.3) 1.62 (0.51–5.20) .538
Receipt of lymphocyte-depleting antibody within pre-
ceding 12 months 7 (24.1) 7 (12.7) 2.18 (0.68–6.98) .223
Allograft rejection within preceding 6 months 13 (44.8) 8 (13.3) 5.28 (1.86–15.00) .001
Lymphocyte count within preceding 30 days,
median cells/mm3 (range) 948 (110–3450) 1245 (153–3770) 1.00 (0.99–1.00) .252
Neutrophil count within preceding 30 days,
median cells/mm3 (range) 4628 (1400–12,063) 4340 (500–17,935) 1.00 (1.00–1.00) .799
NOTE. Data are no. (%) of patients, unless otherwise indicated. CI, confidence interval; CMV, cytomegalovirus; OR, odds ratio; TMP-SMZ,
trimethoprim-sulfamethoxazole.
a Time of event was defined as the time of Listeria infection for the case patients and as the equivalent time for the matched control subjects.
b High-dose prednisone was defined as 20 mg of prednisone for 1 month or 12 pulses of 1 g intravenous methylprednisolone.
c Elevated median calcineurin inhibitor level was defined as 115 mg/mL for tacrolimus and 1300 ng/mL for cyclosporine.
cipients. There were no cases of Listeria infection among 33
pancreas recipients and 7 small bowel recipients. No outbreak
or cluster of cases of listeriosis occurred during the study pe-
riod. No significant differences regarding the trend in the fre-
quency of Listeria infection over time were observed (P p
). The median time to diagnosis of listeriosis after trans-.548
plantation was 202 days (range, 16–5189 days). Fifteen (50%)
of the 30 case patients received a diagnosis of listeriosis 16
months after transplantation.
Risk factors for Listeria infection. The risk factors analyzed
for the 30 case patients and 60 matched control subjects are
shown in Table 1. On univariate analysis, diabetes mellitus,
CMV infection or disease within the preceding 6 months, re-
ceipt of high-dose prednisone within the preceding 6 months,
and the presence of allograft rejection within the preceding 6
months were significantly associated with listeriosis. There were
5 case patients with asymptomatic CMV infection and 3 case
patients with CMV disease.
After applying a conditional logistic regression model (Table
2), diabetes mellitus (OR, 5.6; 95% CI, 1.6–19.6; ),P p .007
history of CMV infection or disease within the preceding 6
months (OR, 35.9; 95% CI, 2.1–620; ), and receipt ofP p .014
high-dose prednisone within the preceding 6 months (OR, 6.2;
95% CI, 1.8–21.1; ) were found to be independentP p .003
risk factors for Listeria infection in SOT recipients, whereas
TMP-SMZ prophylaxis at the time of event was found to be a
protective factor (OR, 0.07; 95% CI, 0.006–0.76; ).P p .029
Clinical characteristics of Listeria infection in SOT
recipients. The clinical characteristics of the 30 SOT recipients
with listeriosis are shown in Table 3. Seventeen patients (56.7%)
were men, with a median age of 58.6 years. The median du-
ration of symptoms prior to hospitalization was 3 days. Twenty-
six patients (86.7%) had bacteremia, and 7 of these patients
had septic shock at presentation. Other manifestations includ-
ed meningoencephalitis, spontaneous peritonitis, pleural em-
pyema, brain abscesses, and liver abscesses. As detailed in
Table 3, 14 transplant recipients (46.7%) with listeriosis had
1 coexisting infection, with the most common coexisting
infection being CMV infection or disease. There was 1 case of
late-onset CMV infection, which occurred 175 days after kid-
ney transplantation.
Microbiology. L. monocytogenes was the species identified
in all cases. The diagnosis of listeriosis was established with the
use of 1 or more of the following methods: blood culture
( ), CSF culture ( ), ascitic fluid culture ( ),n p 26 n p 6 n p 2
pleural fluid culture ( ), liver abscess purulent materialn p 1
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Table 2. Independent Risk Factors for Listeria Infection in Solid-Organ Transplant
Recipients as Defined by Conditional Multivariable Logistic Regression
Variable OR (95% CI) P
Diabetes mellitus 5.6 (1.6–19.6) .007
CMV disease or infection within preceding 6 months 35.9 (2.1–620) .014
Receipt of high-dose prednisone within preceding 6 monthsa 6.2 (1.8–21.1) .003
Receipt of TMP-SMZ prophylaxis 0.07 (0.006–0.76) .029
NOTE. CI, confidence interval; CMV, cytomegalovirus; OR, odds ratio; TMP-SMZ, trimethoprim-
sulfamethoxazole.
a High-dose prednisone was defined as 20 mg of prednisone for 1 month or 12 pulses of 1 g
intravenous methylprednisolone. Variables included in the analysis were sex, age, diabetes mellitus,
CMV disease or infection within the preceding 6 months, receipt of high-dose prednisone within the
preceding 6 months, allograft rejection within the preceding 6 months, and receipt of TMP-SMZ pro-
phylaxis at the time of the event.
culture ( ), and surgical specimen culture of brain abscessn p 1
pus ( ). Serotypes and antimicrobial susceptibility weren p 1
investigated in 13 L. monocytogenes isolates. The most frequent
serotypes were 4 ( ) and 1 ( ). All strains were sus-n p 9 n p 4
ceptible to ampicillin and TMP-SMZ.
Treatment and outcomes. As shown in Table 3, 28 patients
(93.3%) were treated with ampicillin, and 11 of them were also
given gentamicin. The initial intravenous treatment with am-
picillin was switched to oral TMP-SMZ in 11 cases. Two liver
transplant recipients presented with multiple brain and liver
abscesses that required surgical and percutaneous drainage re-
spectively. One heart transplant recipient had an acute episode
of allograft rejection during treatment of listeriosis. Nine pa-
tients (30%) required intensive care unit admission, and 7 of
them underwent mechanical ventilation. The median duration
of antibiotic therapy was 21 days. Excluding patients who died,
the median length of hospital stay was 30 days.
The 30-day mortality rate was 26.7% (8 of 30 patients died).
The median time from diagnosis of listeriosis to death was 15
days (range, 6–29 days). Causes of death were sepsis ( ),n p 4
multiorgan failure ( ), respiratory failure ( ), andn p 2 n p 1
neurological complications ( ). The 30-day mortality raten p 1
was statistically significantly higher among the 10 patients with
meningoencephalitis than it was among the 20 case patients
who presented with other manifestations (60% vs 10%; OR,
13.5; 95% CI, 1.99–93.25; ). The 30-day mortality didP p .007
not differ significantly between patients treated with ampicillin
plus gentamicin and those who received antibiotic monother-
apy (3 [27.3%] of 11 patients vs. 5 [26.3%] of 19 patients; OR,
1.05; 95% CI, 0.19–5.60; )P 1 .99
DISCUSSION
In recent years, the incidence of laboratory-confirmed invasive
listeriosis in the general population in developed countries has
decreased [14]. Surveillance programs have documented rates
of infection ranging from 0.6 through 6.2 cases per million
individuals [15]. The reported incidence of listeriosis among
recipients of allogeneic blood and marrow transplants is much
higher, ranging from 0.39% through 0.47% [16, 17]. To our
knowledge, the frequency of listeriosis among recipients of a
broad range of organ transplant types has not been evaluated.
In the present multicenter study, the prevalence of sporadic
listeriosis among SOT recipients was 0.12%. The prevalence
was highest among the group of multivisceral recipients
(0.29%), followed by liver transplant recipients (0.18%). This
latter figure is similar to that encountered in a study reporting
1 case of listeriosis among 539 liver recipients (0.19%) at a
single institution [5].
In our study, independent risk factors for Listeria infection
in SOT recipients were diabetes mellitus, history of CMV in-
fection or disease within the preceding 6 months, and receipt
of high-dose prednisone within the preceding 6 months,
whereas TMP-SMZ prophylaxis was a protective factor.
Several aspects of immunity, such as polymorphonuclear leu-
kocyte function (ie, leukocyte adherence, chemotaxis, and
phagocytosis) and bactericidal activity of serum are depressed
in patients with diabetes mellitus [18, 19]. Consequently, cer-
tain specific infections are particularly common among these
patients. Previous observational studies have suggested that di-
abetes mellitus may be a predisposing factor for developing
listeriosis [3, 20]. Interestingly, experimental studies have also
linked hyperglycemia to a greater susceptibility to L. monocy-
togenes infection [21]. In our study, 50% of recipients with
listeriosis had diabetes mellitus, compared with 15% of control
subjects. In recent years, posttransplant diabetes mellitus has
emerged as a major adverse event associated with the receipt
of immunosuppressive drugs [22, 23]. Therefore, developing
strategies aimed to minimize this effect should be a focus of
future research.
CMV infection may cause both invasive disease (ie, “direct
effects”) and a variety of secondary immune phenomena in
transplant recipients [24–26]. The immunomodulatory effects
of CMV are increasingly recognized, with previous reports as-
sociating CMV infection with other viral, bacterial, fungal, and
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Table 3. Clinical Characteristics, Treatment, and Outcomes of 30 Solid-Organ
Transplant Recipients with Listeria Infection
Variable Patients
Male sex 17 (56.7)







Temperature 138C 25 (83.3)
Shock at presentation 7 (23.3)
Renal impairmenta 17 (56.7)
Hypoalbuminemiab 21 (70.0)
Manifestations of Listeria infection
Bacteremia 26 (86.7)
Meningoencephalitis 10 (33.3)
Spontaneous peritonitis 2 (6.7)
Pleural empyema 1 (3.3)
Liver abscesses 1 (3.3)
Brain abscesses 1 (3.3)
Coexisting infection 14 (46.7)
CMV infection or disease 7
Primary bacteremia 3




P. aeruginosa tracheobronquitis 1
Invasive pulmonary aspergillosis 1
Nosocomial pneumonia 1




Herpes simplex virus stomatitis 1
ICU admission 9 (30.0)
Mechanical ventilation 7 (23.3)
Other complications 7 (23.3)
Seizures 2
Acute allograft rejection 1
Gastrointestinal bleeding 1







Length of intravenous antibiotic treatment, median days (range)c 21 (3–43)
Length of antibiotic treatment, median days (range)c 21 (7–56)
Length of hospitalization, median days (range)c 30 (7–210)
30-Day mortality 8 (26.7)
NOTE. Data are no. (%) of patients, unless otherwise indicated. CMV, cytomegalovirus;
ICU, intensive care unit; TMP-SMZ, trimethoprim-sulfamethoxazole.
a Renal impairment was defined as a serum creatinine level 11.5 mg/dL.
b Hypoalbuminemia was defined as a serum albumin level !3 g/L.
c Patients who died were excluded from the analysis.
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protozoan infections [27]. Interestingly, CMV disease has been
associated with listeriosis in previous studies of blood and bone
marrow transplantation [16]. Nevertheless, its role as an in-
dependent risk factor for listeriosis in SOT recipients has not
been previously identified. Our data provide additional support
for aggressive management of CMV disease to prevent the “in-
direct” effects of CMV infection.
Prednisone is a broad-acting immunosuppressant, affecting
both the innate and adaptive immune responses. The use of
steroids exerts a decisive influence on the immune function of
macrophages and granulocytes, which are the main cell host
defenses against bacteria. In our study, receipt of high-dose
prednisone within the preceding 6 months was identified as an
independent risk factor for listeriosis. The association of steroid
use and Listeria infection has been well established in previous
studies [6, 7, 28].
At present, SOT recipients are given TMP-SMZ for the first
6 months after transplantation for Pneumocystis jirovecii pneu-
monia prophylaxis in many centers. The routine use of TMP-
SMZ has effectively eliminated this infectious complication [2,
29]. Nevertheless, in a recent study [30], TMP-SMZ prophylaxis
was not shown to be protective against Nocardia infection.
Given the excellent activity of TMP-SMZ against L. monocy-
togenes [31], some investigators have argued that its adminis-
tration might help to prevent listeriosis. In fact, it has been
hypothesized that the low prevalence of this infection among
SOT recipients may be attributable to the use of TMP-SMZ
[28, 32, 33]. However, no study has formally tested this as-
sumption. Significantly, we found that TMP-SMZ prophylaxis
is a protective factor for listeriosis. According to our data, 50%
of cases of listeriosis in SOT recipients occur 16 months after
transplantation. Therefore, extended prophylaxis should be care-
fully considered for patients at high risk of listeriosis (eg, those
with diabetes mellitus, those who receive high-dose prednisone,
and those who develop CMV infection or disease). Moreover,
it should be borne in mind that nearly all cases of listeriosis
are thought to be food-borne [34]. Therefore, all transplant
recipients should be advised to avoid potentially contaminated
foods, such as soft cheeses and unheated delicatessen meals.
They should also be instructed regarding how to reduce the
risk of infection by thorough cooking, avoidance of cross-con-
tamination, and short-term refrigerated storage of perishable
foods [35].
In this study, most of the SOT recipients with L. monocy-
togenes infection had bacteremia. Meningoencephalitis was also
particularly common. Other less common manifestations were
peritonitis, pleural empyema, liver abscesses, and brain ab-
scesses. Other investigators have previously reported similar
clinical manifestations of L. monocytogenes infection in trans-
plant recipients [4, 7, 8, 9, 28].
One recent study found that listeriosis-related deaths among
the general population decreased over the 16-year study period
(1990–2005) [36]. In our study involving SOT recipients, both
the 30-day and 1-year mortality rates were high (26.7% and
33.3%, respectively). The mortality was significantly higher
among patients presenting with meningoencephalitis, reaching
60%. This finding corroborates those of previous reports [37–
40]. Mizuno et al [37] described 1 case of listeriosis after liver
transplantation and reviewed 14 previously reported cases. They
found 4 cases of meningitis, with a mortality rate of 50%.
Similarly, in a review of cases of listeriosis among renal trans-
plant recipients, Stamm et al [38] found that the mortality rate
was higher among patients with meningoencephalitis (37%)
than it was among patients presenting with other manifesta-
tions (11%).
In conclusion, L. monocytogenes infection is uncommon
among SOT recipients but causes high rates of morbidity and
mortality, particularly among patients with meningoenceph-
alitis. Independent risk factors for listeriosis are diabetes mel-
litus, CMV infection or disease, and receipt of high-dose ste-
roids, whereas TMP-SMZ prophylaxis is a protective factor.
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